复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02696 复宏汉霖

已收盘 06-11 16:08:30

56.900

-0.400

-0.70%

最高58.000	最低55.150	成交量50.19万
今开55.300	昨收57.300	日振幅4.97%
总市值308.97亿	流通市值196.92亿	总股本5.43亿
成交额2,827万	换手率0.15%	流通股本3.46亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02696","market":"HK","secType":"STK","nameCN":"复宏汉霖","latestPrice":56.9,"timestamp":1781165310006,"preClose":57.3,"halted":0,"volume":501869,"delay":0,"changeRate":-0.006980802792321093,"floatShares":346074397,"shares":543000000,"eps":1.744799722038945,"marketStatus":"已收盘","change":-0.4,"latestTime":"06-11 16:08:30","open":55.3,"high":58,"low":55.15,"amount":28270555,"amplitude":0.049738,"askPrice":56.9,"askSize":2700,"bidPrice":56.8,"bidSize":4000,"shortable":3,"etf":0,"ttmEps":1.7452412333973277,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781227800000},"marketStatusCode":5,"adr":0,"listingDate":1569340800000,"exchange":"SEHK","adjPreClose":57.3,"openAndCloseTimeList":[[1781141400000,1781150400000],[1781154000000,1781164800000]],"volumeRatio":0.600176,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02696/","defaultTab":"news","newsList":[{"id":"1132988211","title":"复宏汉霖：发行1,706,750股新股，已发行股本变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1132988211","media":"公告速递","labels":["SGX"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132988211?lang=zh_cn&edition=full","pubTime":"2026-06-11 17:37","pubTimestamp":1781170626,"startTime":"0","endTime":"0","summary":"上海复宏汉霖生物技术股份有限公司（股票代码：02696）于2026年6月11日发布翌日披露报表，宣布向公司于2025年7月21日采纳的2025H股受限制股份单位计划之受托人合共配发及发行1,706,750股新股，用于未来归属相关权益。据披露，此次发行股份数量占此前已发行股份总数约0.49%。每股发行价为人民币1元，涉及金额约170.68万元人民币。\n本次发行完成后，公司已发行股本增至347,781,147股，库藏股数保持不变为0股。公司董事会确认，本次股份发行已获得正式授权，并遵守了香港联交所证券上市规则及相关法律法规的要求。公告由董事Wenjie ZHANG签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"复宏汉霖：发行1,706,750股新股，已发行股本变动","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642881072","title":"复宏汉霖(02696)发行合共170.68万股 用于2025年H股受限制股份单位计划归属安排","url":"https://stock-news.laohu8.com/highlight/detail?id=2642881072","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642881072?lang=zh_cn&edition=full","pubTime":"2026-06-11 17:30","pubTimestamp":1781170236,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖(02696)发布公告，公司于2026年6月11日向公司于2025年7月21日采纳的2025H股受限制股份单位计划之受托人配发及发行合共170.68万股新股，以备安排该计划下授予的受限制股份单位的未来归属。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453179.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000320264.USD","BK1161","HK0000306701.USD","HK0000306685.HKD","02696","HK0000165453.HKD","HK0000320223.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642697584","title":"复宏汉霖(02696)：国家药品监督管理局批准汉斯状®(斯鲁利单抗注射液)联合化疗用于胃癌新辅助/辅助治疗新适应症的上市注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2642697584","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642697584?lang=zh_cn&edition=full","pubTime":"2026-06-09 18:12","pubTimestamp":1780999975,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，国家药品监督管理局已批准本公司自主研发的创新抗PD-1单抗汉斯状(汉斯状)联合奥沙利铂和替吉奥用于肿瘤PD-L1表达CPS≥5的可手术切除的胃癌新辅助及手术后单药辅助治疗的新适应症上市注册申请。本次获批的是全球首个在胃癌围术期以免疫单药替代术后辅助化疗的治疗方案，这将进一步增强汉斯状的市场竞争力，同时，亦将为国内胃癌患者带来更多的治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452066.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306701.USD","BK1161","HK0000320223.HKD","HK0000306685.HKD","IPOS","HK0000165453.HKD","HK0000320264.USD","02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122148656","title":"国家药监局批准汉斯状®用于胃癌新辅助/辅助治疗的新药上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1122148656","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122148656?lang=zh_cn&edition=full","pubTime":"2026-06-09 18:11","pubTimestamp":1780999874,"startTime":"0","endTime":"0","summary":"复宏汉霖宣布，其自主研发的创新药汉斯状®（斯鲁利单抗注射液）用于胃癌新辅助/辅助治疗的新药上市申请已获得中国国家药品监督管理局批准。此次获批标志着该药物在消化道肿瘤治疗领域取得又一重要进展，有望为胃癌患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696","HK0000306685.HKD","HK0000165453.HKD","HK0000320223.HKD","HK0000320264.USD","HK0000306701.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642145221","title":"【券商聚焦】中信建投维持复宏汉霖(02696)“买入”评级 指2026年公司催化事件丰富","url":"https://stock-news.laohu8.com/highlight/detail?id=2642145221","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642145221?lang=zh_cn&edition=full","pubTime":"2026-06-09 14:27","pubTimestamp":1780986455,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券发布研报指，复宏汉霖 在2026年ASCO年会上多项临床研究入选，其中HLX43在非小细胞肺癌的II期临床及斯鲁利单抗围手术期胃癌III期研究入选Rapid Oral环节。该研究为全球首个术后免疫单药替代辅助化疗的阳性注册研究。报告强调，2026年公司催化事件丰富，包括斯鲁利单抗在美国及多地区的上市申报、HLX43全球II/III期MRCT推进、HLX22及HLX07等多项数据读出，有望驱动估值重塑。维持“买入”评级。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983345","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641819934","title":"中金：维持复宏汉霖(02696)跑赢行业评级 目标价102.91港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2641819934","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641819934?lang=zh_cn&edition=full","pubTime":"2026-06-05 09:55","pubTimestamp":1780624528,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，维持复宏汉霖当前盈利预测不变，现价交易于27.2倍/25.7倍26/27年市盈率，基于该行公司收入利润稳健增长及HLX43等创新管线的看好，该行维持跑赢行业评级和102.91港元目标价不变，对应47.7倍/45.0倍26/27年市盈率，隐含75%上行空间。中金主要观点如下：公司近况公司在2026 ASCO以快速口头报告形式公布 PD-L1 ADC HLX43在NSCLC两项研究汇总数据，首次披露PFS等数据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450543.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168694642","title":"复宏汉霖5月股份变动月报表：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1168694642","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168694642?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:55","pubTimestamp":1780476943,"startTime":"0","endTime":"0","summary":"上海复宏汉霖生物技术股份有限公司于2026年6月3日发布5月股份变动月报表，报告期为截至2026年5月31日。公告显示，公司未发生新增股份发行、股份回购、注销或库藏股变动，整体已发行股份总数及法定/注册股本均保持稳定。总体而言，报告期内公司总股本维持在543,494,853股，未有新增发行及回购活动。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639601490","title":"每周股票复盘：复星医药（600196）复宏汉霖帕妥珠单抗获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2639601490","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639601490?lang=zh_cn&edition=full","pubTime":"2026-05-31 01:57","pubTimestamp":1780163829,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘，复星医药报收于23.25元，较上周的23.4元下跌0.64%。本周关注点公司公告汇总：复宏汉霖帕妥珠单抗注射液获国家药监局批准上市。复星医药控股子公司复宏汉霖自主研发的帕妥珠单抗注射液获国家药品监督管理局批准上市，适应症覆盖早期乳腺癌和转移性乳腺癌。该药品为帕妥珠单抗生物类似药，已获美国FDA、欧盟委员会批准，并获加拿大卫生部受理。2025年中国境内帕妥珠单抗产品销售额约为27.28亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026053100000394.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK0188","BK0196","BK0028","BK0187","BK1593","BK1161","HK0000320223.HKD","02196","HK0000306701.USD","BK1191","BK0060","HK0000306685.HKD","BK0012","BK0175","HK0000165453.HKD","HK0000320264.USD","600196","BK0096","02696","BK0239","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639628878","title":"复宏汉霖(02696)自主研发的汉倍优于中国境内获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2639628878","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639628878?lang=zh_cn&edition=full","pubTime":"2026-05-29 16:32","pubTimestamp":1780043558,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 公布，近日，公司自主研发的汉倍优(汉倍优)的上市注册申请已获国家药品监督管理局批准。本次汉倍优于中国境内获批上市，丰富了集团于中国乳腺癌市场的商业化产品，汉倍优在将为中国HER2阳性乳腺癌患者带来更多治疗选择的同时，亦有望巩固集团于乳腺癌治疗领域的中国领先地位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447720.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000165453.HKD","HK0000306701.USD","02696","BK1161","HK0000320223.HKD","IPOS","HK0000320264.USD","HK0000306685.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639641092","title":"港股异动 | 复宏汉霖(02696)午后涨超4% HLX43临床研究完成首例给药 关键PFS数据即将披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2639641092","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639641092?lang=zh_cn&edition=full","pubTime":"2026-05-29 14:18","pubTimestamp":1780035517,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖午后涨超4%，截至发稿，涨3.79%，报65.7港元，成交额5153.31万港元。消息面上，复宏汉霖公布，公司创新抗PD-L1抗体偶联药物HLX43用于既往治疗失败的晚期/转移性鳞状非小细胞肺癌治疗的II/III期国际多中心临床研究已在中国完成首例患者给药，标志着该研究在中国正式进入临床实施阶段。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447637.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4211","HK0000165453.HKD","HK0000306685.HKD","HK0000320264.USD","HK0000320223.HKD","PFS","BK4588","VXUS","BK4585","02696","HK0000306701.USD","BK4195"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638665403","title":"复宏汉霖(02696)：注射用HLX43单药或联合 PIMURUTAMAB HLX07对比多西他赛用于既往治疗失败的晚期/ 转移性鳞状非小细胞肺癌治疗的国际多中心2/3期临床研究于中国境内完成首例患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2638665403","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638665403?lang=zh_cn&edition=full","pubTime":"2026-05-28 16:37","pubTimestamp":1779957422,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，注射用HLX43单药或联合pimurutamab HLX07对比多西他赛用于既往治疗失败的晚期/转移性鳞状非小细胞肺癌治疗的国际多中心2/3期临床研究于中国境内完成首例患者给药。本研究的主要目的是评估HLX43单药或HLX43联合HLX07对比多西他赛在经一线治疗失败的晚期鳞状NSCLC患者中的临床疗效，采用总生存期和无进展生存期作为双主要终点。截至本公告日，于全球范围内尚无同类联合用药方案获批上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447117.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306701.USD","BK1161","HK0000165453.HKD","HK0000320223.HKD","HK0000320264.USD","HK0000306685.HKD","02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638597816","title":"复宏汉霖(02696)：HLX15-SC一线治疗新诊断多发性骨髓瘤(NDMM)的国际多中心1期临床研究于中国境内完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2638597816","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638597816?lang=zh_cn&edition=full","pubTime":"2026-05-26 16:54","pubTimestamp":1779785657,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 公布，近日，HLX15-SC一线治疗新诊断多发性骨髓瘤 的国际多中心1期临床研究于中国境内完成首例患者给药。本研究是一项在不适合移植的新诊断多发性骨髓瘤患者中，比较HLX15-SC 和对照药美国市售的DARZALEX FASPRO 联合来那度胺-地塞米松的PK相似性、安全性、耐受性和免疫原性的多中心、随机、双盲、平行对照1期研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445994.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000320223.HKD","HK0000306685.HKD","02696","HK0000306701.USD","HK0000165453.HKD","BK1161","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637317411","title":"复宏汉霖(02696)：斯鲁利单抗注射液获欧洲药品管理局人用医药产品委员会积极审评意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2637317411","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637317411?lang=zh_cn&edition=full","pubTime":"2026-05-22 21:51","pubTimestamp":1779457861,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，公司自主开发的斯鲁利单抗注射液获欧洲药品管理局人用医药产品委员会积极审评意见，推荐批准斯鲁利单抗联合卡铂和白蛋白紫杉醇适用于不可手术切除的局部晚期或转移性鳞状非小细胞肺癌成人患者的一线治疗。一旦获得EC批准，斯鲁利单抗的集中上市许可将在所有欧盟成员国及欧洲经济区国家冰岛、列支敦士登和挪威生效。此次CHMP的积极意见主要是基于一项随机、双盲、国际多中心3期临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445327.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000165453.HKD","09939","02696","HK0000320264.USD","HK0000306701.USD","HK0000306685.HKD","HK0000320223.HKD","159938","BK1515","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197788354","title":"复宏汉霖Serplulimab获欧盟CHMP积极意见，用于鳞状非小细胞肺癌一线治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1197788354","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197788354?lang=zh_cn&edition=full","pubTime":"2026-05-22 21:49","pubTimestamp":1779457773,"startTime":"0","endTime":"0","summary":"上海复宏汉霖生物技术股份有限公司宣布，其核心产品Serplulimab用于联合化疗一线治疗鳞状非小细胞肺癌的上市许可申请，已获得欧洲药品管理局人用药品委员会的积极意见。该结果表明，与单纯化疗相比，Serplulimab联合化疗方案能显著延长患者的无进展生存期和总生存期，且安全性可控。若最终获得批准，这将是Serplulimab在欧盟市场取得的首个适应症，标志着该药物在国际化征程中迈出坚实一步。Serplulimab若成功获批，将为欧盟地区的该类肺癌患者提供新的重要治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000306685.HKD","HK0000320223.HKD","HK0000320264.USD","HK0000165453.HKD","02696","HK0000306701.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637397692","title":"复宏汉霖：注射用HLX316的1期临床于中国境内完成首例给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2637397692","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637397692?lang=zh_cn&edition=full","pubTime":"2026-05-22 17:02","pubTimestamp":1779440520,"startTime":"0","endTime":"0","summary":"5月22日，复宏汉霖（02696）发布公告，近日注射用HLX316（靶向B7-H3的唾液酸酶Fc融合蛋白）在晚期/转移性实体瘤患者中的1期临床研究于中国境内完成首例患者给药。本研究是一项评估HLX316在晚期/转移性实体瘤患者中的安全性、耐受性、药代动力学特征以及初步疗效的开放性、首次人体1期临床研究，研究分为两个阶段：1a期剂量递增及回填阶段和1b期剂量扩展阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605223746786796.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HK0000165453.HKD","HK0000306701.USD","02696","HK0000320264.USD","BK1161","HK0000320223.HKD","HK0000306685.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637860753","title":"复宏汉霖(02696)自主研发的注射用HLX48用于晚期/转移性实体瘤治疗的1期临床试验申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2637860753","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637860753?lang=zh_cn&edition=full","pubTime":"2026-05-21 17:15","pubTimestamp":1779354954,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 公布，近日，公司自主研发的注射用HLX48 用于晚期/转移性实体瘤治疗的1期临床试验申请获国家药品监督管理局批准。因此，HLX48有望实现靶向治疗与免疫调节的双重增效，抑制肿瘤生长并兼具良好安全性。临床前研究显示，HLX48抗肿瘤疗效及安全性良好，其有望获得临床获益。2026年5月，HLX48用于晚期/转移性实体瘤治疗的1期临床试验已获得相关人类研究伦理委员会的批准，并通过澳大利亚药品管理局的临床试验备案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444517.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"复宏汉霖(02696)自主研发的注射用HLX48用于晚期/转移性实体瘤治疗的1期临床试验申请获批","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","HK0000306685.HKD","HK0000306701.USD","HK0000320223.HKD","HK0000320264.USD","HK0000165453.HKD","02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125498263","title":"复宏汉霖获NMPA批准开展HLX48用于晚期/转移性实体瘤的I期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1125498263","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125498263?lang=zh_cn&edition=full","pubTime":"2026-05-21 17:15","pubTimestamp":1779354912,"startTime":"0","endTime":"0","summary":"复宏汉霖宣布，其创新药HLX48已获得中国国家药品监督管理局的临床试验默示许可，将针对晚期或转移性实体瘤患者开展I期临床研究。该批准标志着公司在肿瘤治疗领域的研发管线取得又一重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000320264.USD","HK0000320223.HKD","HK0000306685.HKD","BK1161","HK0000306701.USD","02696","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637802772","title":"复宏汉霖在南京成立新生物技术公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2637802772","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637802772?lang=zh_cn&edition=full","pubTime":"2026-05-21 14:30","pubTimestamp":1779345031,"startTime":"0","endTime":"0","summary":"天眼查App显示，近日，复星汉霖（南京）生物技术有限公司成立，法定代表人为余诚，注册资本5000万元人民币，经营范围为技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广，由复宏汉霖（02696.HK）全资持股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605213744976962.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605213744976962.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HK0000306701.USD","BK1161","HK0000320223.HKD","HK0000306685.HKD","HK0000165453.HKD","HK0000320264.USD","02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636272044","title":"港股异动 | 复宏汉霖(02696)午后涨超4% 近日H药汉斯状®日本一线治疗小细胞肺癌桥接试验完成入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2636272044","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636272044?lang=zh_cn&edition=full","pubTime":"2026-05-18 14:00","pubTimestamp":1779084010,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖午后涨超4%，截至发稿，涨3.19%，报69.65港元，成交额3725.2万港元。消息面上，近日，据复宏汉霖官微消息，公司宣布，其自主研发的创新型抗PD-1单抗H药汉斯状联合化疗一线治疗广泛期小细胞肺癌适应症的日本桥接试验已顺利完成全部受试者入组。NCT06812260以及支持ES-SCLC在中国和欧洲等地获批的ASTRUM-005研究结果，将共同构成支持H药在日本市场注册申报的关键临床数据，并计划携手日本合作伙伴卫材于其2026财年期间递交上市申请。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442808.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306701.USD","HK0000165453.HKD","HK0000320223.HKD","HK0000320264.USD","BK4585","BK4588","VXUS","BK1161","02696","HK0000306685.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635908882","title":"复星医药：目前控股子公司复宏汉霖已收到与Eisai合作项下的首付现金款","url":"https://stock-news.laohu8.com/highlight/detail?id=2635908882","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635908882?lang=zh_cn&edition=full","pubTime":"2026-05-15 17:47","pubTimestamp":1778838457,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：董秘您好，请问：复宏汉霖2026年2月授权卫材的7500万美元首付款，在复星医药2026年一季度合并报表中，是否已确认为当期收入？谢谢。复星医药（600196.SH）5月15日在投资者互动平台表示，截至目前，控股子公司复宏汉霖已收到与Eisai合作项下的首付现金款，并根据会计准则进行会计处理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605153739043716.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605153739043716.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","HK0000165453.HKD","HK0000306701.USD","HK0000320264.USD","02196","BK1161","BK0096","BK1191","BK0028","BK0196","BK0183","BK0175","HK0000320223.HKD","BK0187","600196","BK1515","BK1593","BK0188","BK0012","02696","BK0060","HK0000306685.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0205},{"period":"1month","weight":-0.2257},{"period":"3month","weight":-0.153},{"period":"6month","weight":-0.1157},{"period":"1year","weight":0.1599},{"period":"ytd","weight":0.0044}],"compareEarnings":[{"period":"1week","weight":-0.0478},{"period":"1month","weight":-0.0757},{"period":"3month","weight":-0.0509},{"period":"6month","weight":-0.0604},{"period":"1year","weight":0.0101},{"period":"ytd","weight":-0.0477}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复宏汉霖生物技术股份有限公司是一家主要从事生物制药研发、生物制药服务及生物制药生产与销售的中国公司。该公司的主要产品包括汉曲优（注射用曲妥珠单抗）、汉奈佳（马来酸奈拉替尼片）、汉斯状（斯鲁利单抗注射液）、汉利康（利妥昔单抗注射液）、汉达远（阿达木单抗注射液）、汉贝泰（贝伐珠单抗注射液）等。该公司的产品主要应用于乳腺癌辅助治疗、转移性乳腺癌及转移性胃癌治疗、转移性非鳞状非小细胞肺癌、多关节型幼年特发性关节炎治疗等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.044394},{"month":2,"riseRate":0.714286,"avgChangeRate":0.117695},{"month":3,"riseRate":0.571429,"avgChangeRate":-0.008815},{"month":4,"riseRate":0.857143,"avgChangeRate":0.12138},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.033714},{"month":6,"riseRate":0.571429,"avgChangeRate":0.070404},{"month":7,"riseRate":0.5,"avgChangeRate":0.069459},{"month":8,"riseRate":0.5,"avgChangeRate":-0.024213},{"month":9,"riseRate":0,"avgChangeRate":-0.127435},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.025526},{"month":11,"riseRate":0.571429,"avgChangeRate":0.058675},{"month":12,"riseRate":0.714286,"avgChangeRate":-0.023816}],"exchange":"SEHK","name":"复宏汉霖","nameEN":"HENLIUS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复宏汉霖,02696,复宏汉霖股票,复宏汉霖股票老虎,复宏汉霖股票老虎国际,复宏汉霖行情,复宏汉霖股票行情,复宏汉霖股价,复宏汉霖股市,复宏汉霖股票价格,复宏汉霖股票交易,复宏汉霖股票购买,复宏汉霖股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}